Examining the possible causal relationship between Lung Function, COPD and Alzheimer's Disease. A Mendelian Randomization Study

Daniel H Higbee^{1,2}, Raquel Granell², Esther Walton^{2,3}, Roxanna Korologou-Linden², George Davey Smith², James W Dodd^{1,2}

1 Academic Respiratory Unit, North Bristol NHS Foundation Trust, Bristol, UK

2 MRC Integrative Epidemiology Unit (IEU), University of Bristol, UK.

3 Department of Psychology, University of Bath, Bath, UK

Corresponding Author: Dr James Dodd

Orcid 0000-0003-4805-5759

James.dodd@bristol.ac.uk

Tel +44117 4142012

Fax +44117 4149496

All authors made substantial contributions to analysis, drafting and final approval of the paper. DHH, JWD, RG and GDS were involved in the conception.

Funding: This work was supported by the Medical Research Council and the University of Bristol (MC_UU_12013/1, MC_UU_12013/6). MRC CARP Fellowship

Conflicts of interest: Authors have no conflicts of interest to declare

Abstract

Rationale: Large retrospective case-control studies have reported an association between COPD, reduced lung function and an increased risk of Alzheimer's disease. However, it remains unclear if these diseases are causally linked, or due to shared risk factors. Conventional observational epidemiology suffers from unmeasured confounding and reverse causation. Additional analyses addressing causality are required.

Objectives: To examine a causal relationship between COPD, lung function and Alzheimer's disease.

Methods: Using two-sample Mendelian randomization, we utilised single nucleotide polymorphisms (SNPs) identified in a genome wide association study (GWAS) for lung function as instrumental variables (exposure). Additionally, we used SNPs discovered in a GWAS for COPD in those with moderate to very severe obstruction. The effect of these SNPs on Alzheimer's disease (outcome) were taken from a GWAS based on a sample of 24,807 patients and 55,058 controls.

Results: We found minimal evidence for an effect of either lung function (odds ratio [OR]:1.02 per SD; 95% confidence interval [CI]: 0.91-1.13; p-value 0.68). or liability for COPD on Alzheimer's disease (OR: 0.97 per SD; 95% CI: 0.92 – 1.03; p-value 0.40).

Conclusion: Neither reduced lung function nor liability COPD are likely to be causally associated with an increased risk of Alzheimer's, any observed association is likely due to unmeasured confounding. Scientific attention and health prevention policy may be better focused on overlapping risk factors, rather than attempts to reduce risk of Alzheimer's disease by targeting impaired lung function or COPD directly.

Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a disease of multi-morbidity⁽¹⁾. In COPD the presence of multi-morbidity is associated with higher mortality, worse quality of life and increased healthcare utilisation^(2,3). Impaired lung function measures such as Forced Expiratory Volume in one second (FEV₁) and Forced Expiratory Volume (FVC) have been found to be strongly associated with multi-morbidity.⁽⁴⁾ However, it remains unclear if these multi-morbidities are causally linked to lung function and disease, for example through a proposed inflammatory overspill, or if they are due to shared risk factors, such as smoking⁽⁵⁾. Therapeutic targets may be identified if specific causal mechanisms could be established.

Cognitive impairment is a common co-morbidity in COPD, with reported prevalence ranging from 10-61% and around 25% of older adults with dementia also have COPD⁽⁶⁾. Cognitive impairment in COPD is associated with greater disability⁽⁷⁾, poorer medication compliance,⁽⁸⁾ and risk of exacerbation and mortality⁽⁷⁾. Poor pulmonary function in early life has been associated with increased odds of dementia later in life, even after adjustment for smoking.⁽⁹⁾

Alzheimer's disease (AD) is the most common type of dementia⁽¹⁰⁾, its association with COPD is less well defined than general cognitive ability, but reports of a potential link between COPD and AD was first described nearly 30 years ago⁽¹¹⁾. Large retrospective observational case-control cohorts have reported increased risk of AD in patients with both COPD and reduced lung function^(12,13). For example, Lutsey et al reviewed hospitalisation codes⁽¹³⁾ in the Atherosclerosis Risk In Communities Study for AD-related outcomes and reported that an Odds Ratio of 1.24 for AD-type dementia or mild cognitive impairment (MCI) in patients with COPD and OR 1.79 for those with a restrictive impairment compared

to controls. If the lung function and COPD have a causal effect on risk of Alzheimer's disease, then they could be modifiable risk factors.

Mendelian Randomization (MR) is an established genetic epidemiological method which can overcome problems of unmeasured confounders and reverse causation, typical of conventional observational epidemiology⁽¹⁴⁾. MR allows causal inference through the use of genetic variants as proxies for non-genetic (modifiable) risk factors or health outcomes⁽¹⁴⁾. MR uses genetic data, e.g. single nucleotide polymorphisms (SNPs) that are associated with an exposure (in this case diagnosis of COPD or lung function), and uses them as instrumental variables (IV) to assess the causal effect of the exposure on the outcome of interest (in this case Alzheimer's disease)⁽¹⁵⁾.

MR has multiple advantages. Genetic variants are randomly allocated at birth which can be exploited to simulate randomisation⁽¹⁵⁾. They are not influenced by behavioural or environmental factors minimizing reverse causality (where the outcome, or early stages of the disease process that leads to the outcome, influences the exposure)⁽²⁰⁾. Additionally, the effects are equivalent to lifetime differences, reducing issues relating to transient fluctuations. Our objective was to use MR to investigate if there is any evidence of a causal effect between the exposures, lung function and liability to COPD and the outcome, Alzheimer's disease.

Methods

Lung Function

We used data from Shrine et al. the largest currently available lung function GWAS, $n=400,102$ ⁽¹⁶⁾ which reported 279 genome wide significant SNPs ($p<5\times 10^{-9}$). Lung function measurements used were Forced Expiratory Volume in 1 second (FEV_1), Forced Vital Capacity (FVC), FEV_1/FVC ratio and Peak Expiratory Flow (PEF). A weighted risk score, was associated with risk of COPD ($p=6.64\times 10^{-63}$), with an Odds ratio of 1.55 for each standard deviation of the risk score ^(16, 17). Further details of the study population can be found in the supplementary information and the reference ⁽¹⁶⁾.

COPD

We used 82 SNPs associated with COPD, as identified in Sarkonsakaplat et al. case control GWAS⁽¹⁸⁾, $n=35,735$ cases and 222,076 controls discovered in meta-analysis of 25 studies. COPD was defined by Global Initiative for Chronic Obstructive Lung Disease criteria; $FEV_1/FVC < 0.7$ and $FEV_1 < 80\%$ predicted. Further details of study population can be found in the supplementary information and the reference.⁽¹⁸⁾

80% and 77% of the Shrine et al and Sarkonsakaplat et al GWAS sample respectively were from the UK Biobank ⁽¹⁹⁾. In brief the UK Biobank is a large prospective cohort study where >500,000 participants were recruited from 2006 – 2010 in the United Kingdom (54% female). Pre-bronchodilation lung function testing was performed by trained healthcare staff.

Alzheimer's disease

We used data from a meta-analysis of the International Genomics of Alzheimer's disease (IGAP) consortium⁽²⁰⁾, Alzheimer's Disease Sequencing Project (ADSP) ⁽²¹⁾, and Psychiatric Genomics Consortium (PGC) ⁽²²⁾ totalling 24,807 Alzheimer's disease cases and 55,058 controls ⁽²³⁾. All cases had clinical diagnoses of Alzheimer's disease. Some participants of the ADSP cohort were previously also included in IGAP, so ADSP individuals that were

duplicates based on the comparison of individual level genetic data between IGAP and ADSP were excluded.

There was no sample overlap between the exposure and outcome samples. All participants were of European ancestry.

Statistical Analysis

Statistical analysis was done using R Studio version 3.5.1. and the MRCIEU/TwoSampleMR R package⁽²⁴⁾.

For exposure traits r^2 was estimated for each genetic instrument and used to determine the Cragg-Donald overall F-statistic.⁽²⁵⁾ The higher the F-statistic the lower the chance of weak instrument bias.⁽²⁵⁾ For all exposures SNPs LD-clumping was performed using European reference population (kb = 10000, r^2 0.001). Palindromic SNPs (i.e. A/T and C/G SNPs) with intermediate allele frequencies were excluded. The remaining SNPs were harmonised⁽²⁶⁾. Steiger filtering⁽²⁷⁾ was performed to remove variants that caused more variance of the outcome than the exposure, see online supplement for more details.

Main Mendelian Randomization Analysis

Inverse Variance Weighting (IVW) was used for main effect estimate. This is a weighted regression of SNP-outcome on SNP-exposure associations combined where the y intercept is constrained to zero.

Assumption and Sensitivity Analysis

MR assumptions and further details of tests used, are detailed in the online appendix. To account for the possibility of horizontal pleiotropy (IVs influence exposure and outcome through independent pathways), we performed MR Egger. To minimise the effect of unbalanced instruments on an overall estimate of the mean, weighted median and mode MR methods were performed. To assess for horizontal pleiotropy a funnel plot was made by

133 plotting the effect against its precision (beta against standard error). To ensure the results
 134 were not due to outliers with a large effect, a leave-one-out analysis was performed by re-
 135 estimating the total effect after sequentially excluding one SNP at a time and a single-SNP
 136 analysis, where the effect of each SNP was individually assessed via IVW analysis and
 137 represented in a forest plot.

138 Heterogeneity (the variability in causal estimates obtained for each SNP) is an indication of
 139 potential violation of assumptions. This was calculated and assessed with a Q statistic.

Results

F-statistic for lung function GWAS⁽¹⁶⁾ exposures were; All traits=111, FEV₁=69, FVC=70, FEV₁/FVC=148, making weak instrument bias unlikely. After clumping, extracting SNPs from outcome GWAS, Steiger filtering and removal of palindromic SNPs, 131 SNPs were available for analysis. See flow charts in supplementary information for detailed analysis pathway.

We found minimal evidence for a causal effect of lung function (all traits) on Alzheimer's disease, (IVW odds ratio [OR]:1.02 per SD; 95% CI: 0.91-1.13; p-value 0.68). This result was further confirmed in a sensitivity analysis using both weighted median (OR:1.01 per SD; 95% CI:0.86-1.19, p value = 0.81), and weighted mode MR (OR 0.99 per SD;95% CI 0.78-1.19), p-value = 0.81). risk of AD. The MR-Egger causal estimation produced similar results with an OR 1.05 per SD (95% CI 0.79-1.34; p-value 0.71). The confidence interval of the MR-Egger is wider than that of IVW, consistent with the lower statistical power of this test.

Figure 1 plots each individual SNP-exposure effect against SNP-outcome with the coloured lines representing each statistical test. Increasing lung function (exposure) does not have a consistent effect on Alzheimer's disease (outcome).

Table 1 shows that these results were consistent when analysing lung function traits FEV₁, FVC, and FEV₁/FVC individually with little evidence of a causal association on Alzheimer's disease with confidence intervals crossing 1 for all statistical tests.

Table 1. Two-sample MR results of lung function traits⁽¹⁶⁾ on Alzheimer's disease⁽²³⁾

		Lung Function Trait (Exposure)			
		FEV ₁ , FVC, FEV ₁ /FVC, PEF	FEV ₁	FVC	FEV ₁ /FVC
No. SNPs used		131	42	46	73
IVW	OR per SD	1.02	1.04	1.08	0.99
	(95% CI)	(0.91 – 1.13)	(0.82 – 1.32)	(0.85 – 1.37)	(0.88 – 1.13)
	p-Value	0.68	0.73	0.51	0.97
	Q_p-value*	0.26	0.30	0.19	0.71
Weighted Median	OR per SD	1.01	1.15	1.14	0.95
	(95% CI)	(0.86 – 1.19)	(0.82 – 1.61)	(0.83 – 1.58)	(0.79 – 1.15)
	p-Value	0.81	0.39	0.39	0.62
Weighted Mode	OR per SD	0.99	1.07	1.04	0.97
	(95% CI)	(0.78 – 1.26)	(0.60 - 1.90)	(0.61 – 1.78)	(0.74 – 1.26)
	p-Value	0.97	0.80	0.86	0.84
MR- Egger	OR per SD	1.05	1.22	0.97	0.95
	(95% CI)	(0.79 – 1.34)	(0.57 - 2.59)	(0.36 – 2.62)	(0.69 – 1.31)
	p-Value	0.71	0.59	0.96	0.77

*A test for heterogeneity. If this was <0.05 it would suggest heterogeneity

OR – Odd ratio; CI – Confidence Interval; IVW – Inverse Variance Weighting

We used single-SNP analyses to determine the effect of each lung function SNP on the odds of Alzheimer's disease (**Figure 2**). The SNP rs2070600, may be an outlier due to its comparatively large effect on both lung function and AD. Polymorphisms in this SNP have been described as having a weak effect on Alzheimer's disease risk.⁽²⁸⁾ However, despite excluding this SNP from the analysis the results were similar (e.g. see leave-one-out analysis in **Figure 3**).

Each SNP beta was plotted against its inverse standard error (**Figure 4**) producing a funnel shape indicating no heterogeneity. In addition to these visual tests, we found little evidence of heterogeneity using a Q statistic when lung function traits were combined or assessed

individually (**Table 1**. Q_p value >0.51). MR-Egger intercept was <0.001 , visually displayed in **Figure 1**, indicating there was no unbalanced horizontal pleiotropy.

Using the COPD GWAS⁽¹⁸⁾ gave an F-statistic of 52. After clumping, extracting SNPs from outcome GWAS, Steiger filtering and removal of palindromic SNPs, 53 SNPs for liability to COPD were available for analysis in the Alzheimer's outcome GWAS. Please see flow chart in supplementary information for details. Results are displayed in **Table 2**.

Table 2. Two-sample MR results of COPD⁽¹⁸⁾ on Alzheimer's disease⁽²⁹⁾

COPD		
No. SNPs used		53
IVW	OR per SD (95% CI)	0.97 (0.92 – 1.03)
	p-Value	0.40
	Q_p -value	0.57
Weighted Median	OR per SD (95% CI)	0.97 (0.90 – 1.05)
	p-Value	0.52
Weighted Mode	OR per SD (95% CI)	0.96 (0.86 – 1.08)
	p-Value	0.56
MR-Egger	OR per SD (95% CI)	1.10 (0.93 – 1.31)
	p-Value	0.23

OR – Odd ratio; CI – Confidence Interval; IVW – Inverse Variance Weighting

We found minimal evidence for an effect of liability to COPD on risk of Alzheimer's disease (IVW OR: 0.97 per SD; 95% CI: 0.92 – 1.03; p-value 0.40). This result was further confirmed in our sensitivity analysis using both weighted median (OR: 0.97 per SD; 95% CI: 0.90-1.05; p-value = 0.52), and weighted mode MR (OR: 0.96 per SD; 95% CI: 0.86-1.08; p-value = 0.56). The MR-Egger causal estimation produced an OR 1.11 per SD (95% CI: 0.93-1.31; p-value 0.2), the only test to show a direction of effect of increasing COPD causing

197 increased risk of Alzheimer's disease. **Figures 5-8** are available in supplementary
198 information, demonstrating that results were not driven by an individual SNP. There was no
199 evidence of heterogeneity, with a Q-pvalue 0.57.

200

Discussion

Evidence before this study

Our results indicate that there is minimal evidence of a causal association between lung function or liability to COPD and risk of Alzheimer's disease. This is in contrast to two large observational studies^(12, 13), which do report an association between COPD and Alzheimer's disease. The observed associations may be due to unmeasured confounding by risk factors common to both COPD and Alzheimer's disease such as smoking, physical inactivity, social deprivation and lower educational attainment⁽³⁰⁾. The observational studies may have inadvertently included other forms of dementia other than Alzheimer's disease, for example vascular dementia resulting from cerebrovascular or neurological damage. Apolipoprotein e4 allele is the biggest risk factor for Alzheimer's disease whereas it is thought that COPD affects cognition via vascular effects. There is evidence that COPD and reduced lung function is associated with micro and macrovascular damage that could mediate the relationship.⁽³¹⁻³³⁾ It is possible that vascular dementia is causally linked to COPD and lung function, but this outcome was not included in our analysis which was restricted to Alzheimer's disease only. Cognitive dysfunction and Mild Cognitive Impairment are well described in COPD⁽⁶⁾. It may be that this association is causal, but that patients do not progress to Alzheimer's disease due to their lung disease. Survivor bias (where selection is conditional upon survival to recruitment⁽³⁴⁾) can be of concern in studies involving potentially fatal diseases of later life. Potentially, patients with COPD would be less likely to be recruited to a GWAS, biasing the MR towards a null. Observational studies performed by analysing health records may be less likely to be affected by this.

Impact of this study

This analysis uses two-sample MR and multivariable MR to explore a causal association between lung function, COPD and Alzheimer's disease. The increasing incidence of

Alzheimer's disease in Western society has been described as an epidemic⁽³⁵⁾. COPD is responsible for 5% of global disability-adjusted life years and 5% of total deaths⁽³⁶⁾. Consequently, prevention and treatment of both COPD and Alzheimer's disease is a global health priority. Although there have been efforts to search for causal mechanisms linking the two diseases, our analysis using multiple means of assessing causation would suggest scientific attention and health prevention resources may be better focused on overlapping risk factors such as smoking, diet and physical activity^(37,38), rather than attempts to reduce risk of AD by improving lung function or reducing liability to COPD alone.

Strengths and Limitations

By using randomly assigned genetic variants as an exposure, two-sample MR methodology eliminates many confounders in observational epidemiology⁽¹⁴⁾. We used a large number of robust lung function SNPs, which have been well validated in large samples.^(16,18) It is important to ensure that the assumptions of MR are met when dealing with SNPs for complex phenotypes like lung function and COPD. We adhered to proposed methodological guidelines of MR (STROBE)⁽³⁹⁾ which are designed to increase reliability of MR reporting. None of the sensitivity tests provided strong evidence for a violation of the MR assumptions. COPD is a binary trait, so our SNPs confer liability to COPD. As this is a Two Sample MR study, we do not know how many participants in the outcome population had COPD. COPD is a clinical diagnosis with set spirometric thresholds, whereas in the discovery GWAS a diagnosis of COPD was made based on spirometric criteria alone. This was done by dichotomising continuous traits. Dichotomization of continuous traits in MR studies can make interpretation of the causal estimate less reliable, but MR can still be a valid test of the causal null hypothesis for a binary exposure.⁽⁴⁰⁾

As the SNPs were discovered in populations of those with European ancestry, the results may not be generalisable to other populations. However, we believe the findings of this study are likely to be generalisable to the non-European population as a genetic risk score of the lung function SNPs was validated in other ancestral populations, with slightly reduced effect ⁽¹⁶⁾.

Conclusions

Lung function and liability to COPD are not causally associated with an increased risk of Alzheimer's disease. Previous observational studies showing an association between impaired lung function or COPD and Alzheimer's disease are most likely due to unmeasured confounding.

Acknowledgements

We acknowledge participants and investigators of the IGAP⁽²⁰⁾, ADSP⁽²¹⁾, PGC⁽²²⁾, UKBiobank and Spirometa groups, and the authors of the Alzheimer's disease⁽²³⁾ lung function⁽¹⁶⁾ and COPD⁽¹⁸⁾ GWAS.

References

1. Schwab P, Dhamane AD, Hopson SD, Moretz C, Annavarapu S, Burslem K, Renda A, Kaila S. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population. *International journal of chronic obstructive pulmonary disease* 2017; 12: 735-744.
2. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. *The European respiratory journal* 2006; 28: 1245-1257.
3. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. *The European respiratory journal* 2008; 32: 962-969.
4. Agusti A, Noell G, Brugada J, Faner R. Lung function in early adulthood and health in later life: a transgenerational cohort analysis. *The Lancet Respiratory medicine* 2017; 5: 935-945.
5. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. *The European respiratory journal* 2009; 33: 1165-1185.
6. Dodd JW. Lung disease as a determinant of cognitive decline and dementia. *Alzheimer's research & therapy* 2015; 7: 32.
7. Chang SS, Chen S, McAvay GJ, Tinetti ME. Effect of coexisting chronic obstructive pulmonary disease and cognitive impairment on health outcomes in older adults. *Journal of the American Geriatrics Society* 2012; 60: 1839-1846.
8. Incalzi RA, Gemma A, Marra C, Capparella O, Fuso L, Carbonin P. Verbal Memory Impairment in COPD: Its Mechanisms and Clinical Relevance. *Chest* 1997; 112: 1506-1513.
9. Gilsanz P, Mayeda ER, Flatt J, Glymour MM, Quesenberry CP, Jr., Whitmer RA. Early Midlife Pulmonary Function and Dementia Risk. *Alzheimer disease and associated disorders* 2018; 32: 270-275.
10. Silva MVF, Loures CdMG, Alves LCV, de Souza LC, Borges KBG, Carvalho MdG. Alzheimer's disease: risk factors and potentially protective measures. *J Biomed Sci* 2019; 26: 33-33.
11. Incalzi RA, Gemma A, Marra C, Muzzolon R, Capparella O, Carbonin P. Chronic obstructive pulmonary disease. An original model of cognitive decline. *The American review of respiratory disease* 1993; 148: 418-424.
12. Liao KM, Ho CH, Ko SC, Li CY. Increased Risk of Dementia in Patients With Chronic Obstructive Pulmonary Disease. *Medicine* 2015; 94: e930.
13. Lutsey PL, Chen N, Mirabelli MC, Lakshminarayan K, Knopman DS, Vossell KA, Gottesman RF, Mosley TH, Alonso A. Impaired Lung Function, Lung Disease and Risk of Incident Dementia. *American journal of respiratory and critical care medicine* 2018.
14. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Human Molecular Genetics* 2014; 23: R89-R98.
15. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. *Statistical methods in medical research* 2017; 26: 2333-2355.
16. Shrine N, Guyatt AL, Erzurumluoglu AM, Jackson VE, Hobbs BD, Melbourne CA, Batini C, Fawcett KA, Song K, Sakornsakolpat P, Li X, Boxall R, Reeve NF, Obeidat Me, Zhao JH, Wielscher M, Weiss S, Kentistou KA, Cook JP, Sun BB, Zhou J, Hui J, Karrasch S, Imboden M, Harris SE, Marten J, Enroth S, Kerr SM, Surakka I, Vitart V, Lehtimäki T, Allen RJ, Bakke PS, Beaty TH, Bleeker ER, Bossé Y, Brandsma C-A, Chen Z, Crapo JD, Danesh J, DeMeo DL, Dudbridge F, Ewert R, Gieger C, Gulsvik A, Hansell AL, Hao K, Hoffman JD, Hokanson JE, Homuth G, Joshi PK, Joubert P, Langenberg C, Li X, Li L, Lin K, Lind L, Locantore N, Luan Ja, Mahajan A, Maranville JC, Murray A, Nickle DC, Packer R, Parker MM, Paynton ML, Porteous DJ, Prokopenko D, Qiao D, Rawal R, Runz H, Sayers I, Sin DD, Smith BH, Soler Artigas M, Sparrow D, Tal-Singer R, Timmers PRHJ, Van den Berge M, Whittaker JC, Woodruff PG, Yerges-Armstrong LM, Troyanskaya OG, Raitakari OT, Kähönen M, Polašek O, Gyllenstein U, Rudan I, Deary IJ, Probst-Hensch NM, Schulz H, James AL, Wilson JF, Stubbe B, Zeggini E, Jarvelin M-R, Wareham N, Silverman EK, Hayward C, Morris AP, Butterworth AS, Scott RA, Walters RG,

- Meyers DA, Cho MH, Strachan DP, Hall IP, Tobin MD, Wain LV, Understanding Society Scientific G. New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. *Nature Genetics* 2019; 51: 481-493.
17. Wain L, Shrine N, Guyatt A, Jackson V, Erzurumluoglu AM, Batini C, Reeve N, Hobbs B, Cho M, Strachan D, Morris A, Hall I, Tobin M. A weighted genetic risk score based on 279 signals of association with lung function predicts Chronic Obstructive Pulmonary Disease. *European Respiratory Journal* 2018; 52: OA2188.
18. Sakornsakolpat P, Prokopenko D, Lamontagne M, Reeve NF, Guyatt AL, Jackson VE, Shrine N, Qiao D, Bartz TM, Kim DK, Lee MK, Latourelle JC, Li X, Morrow JD, Obeidat Me, Wyss AB, Bakke P, Barr RG, Beaty TH, Belinsky SA, Brusselle GG, Crapo JD, de Jong K, DeMeo DL, Fingerlin TE, Gharib SA, Gulsvik A, Hall IP, Hokanson JE, Kim WJ, Lomas DA, London SJ, Meyers DA, O'Connor GT, Rennard SI, Schwartz DA, Sliwinski P, Sparrow D, Strachan DP, Tal-Singer R, Tesfaigzi Y, Vestbo J, Vonk JM, Yim J-J, Zhou X, Bossé Y, Manichaikul A, Lahousse L, Silverman EK, Boezen HM, Wain LV, Tobin MD, Hobbs BD, Cho MH, Shrine N, Guyatt AL, Batini C, Zhao JH, Wielscher M, Weiss S, Kentistou KA, Cook JP, Hui J, Karrasch S, Imboden M, Harris SE, Marten J, Enroth S, Kerr SM, Surakka I, Vitart V, Lehtimäki T, Ewert R, Gieger C, Homuth G, Joshi PK, Langenberg C, Lind L, Luan Ja, Mahajan A, Murray A, Porteous DJ, Rawal R, Smith BH, Timmers PRHJ, Raitakari OT, Kähönen M, Polasek O, Gyllenstein U, Rudan I, Deary IJ, Probst-Hensch NM, Schulz H, James AL, Wilson JF, Stubbe B, Zeggini E, Jarvelin M-R, Wareham N, Hayward C, Morris AP, Strachan DP, Hall IP, Tobin MD, Wain LV, Agusti A, Anderson W, Bakerly N, Bakke P, Bals R, Barnes KC, Barr RG, Beaty TH, Bleecker ER, Boezen HM, Bossé Y, Bowler R, Brightling C, de Bruijne M, Castaldi PJ, Celli B, Cho MH, Coxson HO, Crapo JD, Crystal R, de Jong P, Dirksen A, Dy J, Foreman M, Garcia-Aymerich J, Gevenois P, Ghosh S, Gietema H, Gulsvik A, Hall IP, Hansel N, Hersh CP, Hobbs BD, Hoffman E, Kalsheker N, Kauczor H-U, Kim WJ, Kim DK, Laitinen T, Lambrechts D, Lee S-D, Litonjua AA, Lomas DA, London SJ, Loth DW, Lutz SM, Lynch D, MacNee W, McDonald M-L, Meyers DA, Newell JD, Nordestgaard BG, O'Connor GT, Obeidat Me, Oh Y-M, Paré PD, Pistolesi M, Postma DS, Puhan M, Regan E, Rich SS, Seo JB, Short A, Silverman EK, Sparrow D, Stoel B, Strachan DP, Sverzellati N, Tal-Singer R, ter Riet G, Tesfaigzi Y, Tobin MD, Van Beek EJR, van Ginneken B, Vestbo J, Vogelmeier CF, Wain LV, Wanner A, Washko G, Wauters E, Wouters EFM, Young RP, Zeigler-Heitbrock L, SpiroMeta C, Understanding Society Scientific G, International CGC. Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. *Nature Genetics* 2019; 51: 494-505.
19. <https://www.ukbiobank.ac.uk/>.
20. Lambert J-C, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, Jun G, DeStefano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thornton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin C-F, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau M-T, Choi S-H, Reitz C, Pasquier F, Hollingworth P, Ramirez A, Hanon O, Fitzpatrick AL, Buxbaum JD, Campion D, Crane PK, Baldwin C, Becker T, Gudnason V, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Morón FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fiévet N, Huentelman MJ, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuinness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossù P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Naranjo MCD, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F, European Alzheimer's Disease I, Genetic, Environmental Risk in Alzheimer's D, Alzheimer's Disease Genetic C, Cohorts for H, Aging Research in Genomic E, Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannfelt L, Hakonarson H, Pichler S, Carrasquillo MM,

- 366 Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson
367 KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O,
368 O'Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley Jr TH, Bennett DA, Harris
369 TB, Fratiglioni L, Holmes C, de Bruijn RFAG, Passmore P, Montine TJ, Bettens K, Rotter JI,
370 Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K,
371 Lunetta KL, Kauwe JSK, Boerwinkle E, Riemenschneider M, Boada M, Hiltunen M, Martin ER,
372 Schmidt R, Rujescu D, Wang L-S, Dartigues J-F, Mayeux R, Tzourio C, Hofman A, Nöthen MM,
373 Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ,
374 Farrer LA, van Duijn CM, Van Broeckhoven C, Moskva V, Seshadri S, Williams J,
375 Schellenberg GD, Amouyel P. Meta-analysis of 74,046 individuals identifies 11 new
376 susceptibility loci for Alzheimer's disease. *Nature Genetics* 2013; 45: 1452.
- 377 21. dbGaP. Genotypes and Phenotypes. [cited 2019. Available from:
378 https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000572.v7.p4.
- 379 22. Medicine USO. 2019. Available from: [https://www.med.unc.edu/pgc/pgc-](https://www.med.unc.edu/pgc/pgc-workgroups/alzheimers-disease-workgroup/)
380 [workgroups/alzheimers-disease-workgroup/](https://www.med.unc.edu/pgc/pgc-workgroups/alzheimers-disease-workgroup/).
- 381 23. Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, Sealock J, Karlsson IK, Hägg
382 S, Athanasiu L, Voyle N, Proitsi P, Witoelar A, Stringer S, Aarsland D, Almdahl IS, Andersen F,
383 Bergh S, Bettella F, Björnsson S, Brækhus A, Bråthen G, de Leeuw C, Desikan RS, Djurovic S,
384 Dumitrescu L, Fladby T, Hohman TJ, Jonsson PV, Kiddle SJ, Rongve A, Saltvedt I, Sando SB,
385 Selbæk G, Shaoi M, Skene NG, Snaedal J, Stordal E, Ulstein ID, Wang Y, White LR, Hardy J,
386 Hjerling-Leffler J, Sullivan PF, van der Flier WM, Dobson R, Davis LK, Stefansson H, Stefansson
387 K, Pedersen NL, Ripke S, Andreassen OA, Posthuma D. Genome-wide meta-analysis identifies
388 new loci and functional pathways influencing Alzheimer's disease risk. *Nature Genetics* 2019;
389 51: 404-413.
- 390 24. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J,
391 Langdon R, Tan VY, Yarmolinsky J, Shihab HA, Timpson NJ, Evans DM, Relton C, Martin RM,
392 Davey Smith G, Gaunt TR, Haycock PC. The MR-Base platform supports systematic causal
393 inference across the human phenome. *eLife* 2018; 7.
- 394 25. Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in Mendelian
395 randomization studies. *International journal of epidemiology* 2011; 40: 755-764.
- 396 26. Haycock PC, Burgess S, Wade KH, Bowden J, Relton C, Davey Smith G. Best (but oft-forgotten)
397 practices: the design, analysis, and interpretation of Mendelian randomization studies. *Am J*
398 *Clin Nutr* 2016; 103: 965-978.
- 399 27. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely
400 measured traits using GWAS summary data. *PLoS genetics* 2017; 13: e1007081.
- 401 28. Daborg J, von Otter M, Sjölander A, Nilsson S, Minthon L, Gustafson DR, Skoog I, Blennow K,
402 Zetterberg H. Association of the RAGE G82S polymorphism with Alzheimer's disease. *Journal*
403 *of neural transmission (Vienna, Austria : 1996)* 2010; 117: 861-867.
- 404 29. Jansen H, Lieb W, Schunkert HJCD, Therapy. Mendelian Randomization for the Identification of
405 Causal Pathways in Atherosclerotic Vascular Disease. 2016; 30: 41-49.
- 406 30. Crous-Bou M, Minguillón C, Gramunt N, Molinuevo JL. Alzheimer's disease prevention: from risk
407 factors to early intervention. *Alzheimer's research & therapy* 2017; 9: 71-71.
- 408 31. McKay GJ, McCarter RV, Hogg RE, Higbee DH, Bajaj MK, Burrage DR, Ruickbie S, Baker EH, Jones
409 PW, Dodd JW. Simple non-mydratic retinal photography is feasible and demonstrates retinal
410 microvascular dilation in Chronic Obstructive Pulmonary Disease (COPD). *PloS one* 2020; 15:
411 e0227175.
- 412 32. Liao D, Higgins M, Bryan NR, Eigenbrodt ML, Chambless LE, Lamar V, Burke GL, Heiss G. Lower
413 pulmonary function and cerebral subclinical abnormalities detected by MRI: the
414 Atherosclerosis Risk in Communities study. *Chest* 1999; 116: 150-156.

33. Dodd JW, Chung AW, van den Broek MD, Barrick TR, Charlton RA, Jones PW. Brain structure and function in chronic obstructive pulmonary disease: a multimodal cranial magnetic resonance imaging study. *American journal of respiratory and critical care medicine* 2012; 186: 240-245.
34. Vansteelandt S, Dukes O, Martinussen T. Survivor bias in Mendelian randomization analysis. *Biostatistics* 2017; 19: 426-443.
35. Johnson N, Davis T, Bosanquet N. The Epidemic of Alzheimer's Disease. *PharmacoEconomics* 2000; 18: 215-223.
36. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet (London, England)* 2012; 380: 2095-2128.
37. Xu W, Tan L, Wang HF, Jiang T, Tan MS, Tan L, Zhao QF, Li JQ, Wang J, Yu JT. Meta-analysis of modifiable risk factors for Alzheimer's disease. *Journal of neurology, neurosurgery, and psychiatry* 2015; 86: 1299-1306.
38. Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. *The Lancet* 2015; 385: 899-909.
39. Davey Smith G DN, Dimou N, Egger M, Gallo V, Golub R, Higgins JP, Langenberg C, Loder EW, Richards JB, Richmond RC, Skrivankova VW, Swanson SA, Timpson NJ, Tybjaerg-Hansen A, VanderWeele TJ, Woolf BA, Yarmolinsky J. STROBE-MR: Guidelines for strengthening the reporting of Mendelian randomization studies. *PeerJ Preprints* 2019; 7:e27857v1.
40. Burgess S, Labrecque JA. Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates. *Eur J Epidemiol* 2018; 33: 947-952.

Figure 1. Scatter plot of the SNP-effect on lung function trait and SNP-effect on Alzheimer's disease

Each point on the graph represents the SNP-outcome association plotted against the SNP-exposure association. Bars indicate 95% confidence intervals. Coloured lines represent analysis method used. This shows no effect of lung function on Alzheimer's disease. MR Egger intercept is close to zero indicating no unbalanced directional pleiotropy.

Figure 2. Single SNP analysis of lung function traits on Alzheimer's disease

Each point represents individual SNP calculated effect size for lung function on the odds of Alzheimer's disease. Bars indicate 95% CI.

Figure 3. Leave-one-out analysis of lung function traits on Alzheimer's disease

Each point represents the IVW estimate if the SNP on the y axis was left out of total analysis.

Bars indicate 95% confidence intervals, demonstrating that no individual SNP is driving the causal effect estimate.

Figure 4. Funnel plot of heterogeneity of causal effects of lung function traits on Alzheimer's disease

Each point is a SNP with its beta plotted against its inverse standard error. As the graph is funnel shaped, it indicates no heterogeneity.

Online Data Supplement

Examining the possible causal relationship between Lung Function, COPD and Alzheimer's Disease. A Mendelian Randomization Study

Daniel H Higbee, Raquel Granell, Esther Walton, Roxanna Korologou-Linden, George Davey Smith, James W Dodd

Contents

Appendix 1. Figures for COPD specific SNPs

Appendix 2. Assumptions and tests

Appendix 3. Details of sample populations

Appendix 4. Flow chart of analyses

Appendix 5. Data and code availability

Appendix 1. Figures for COPD SNPs

Figure E1. Scatter Plot of IVW COPD and AD

Each point on the graph represents the SNP-outcome association plotted against the SNP-exposure association. Bars indicate 95% confidence intervals. Coloured lines represent analysis method used. This shows no significant effect of COPD on Alzheimer's disease. MR Egger intercept is close to zero indicating no unbalanced directional pleiotropy.

Figure E2. Single SNP Analysis of COPD and AD

Each point represents individual SNP calculated effect size for COPD on odds of Alzheimer's disease. Bars indicate 95% CI.

Figure E3. Leave one out analysis of COPD and AD

Each point represents the IVW estimate if the SNP on the y axis was left out of total analysis.

Bars indicate 95% confidence intervals. It demonstrates that no individual SNP is driving the causal effect estimate.

Figure E4. Funnel Plot analysis of COPD and AD

Each point is a SNP with its beta plotted against its inverse standard error. As the graph is funnel shaped, it indicates no heterogeneity.

Appendix 2

Assumptions

We assume that our IVs have a true association with the exposures. This has been rigorously statistically tested in the discovery GWAS and effect estimation ^(1, 2). F-statistic calculation shows that all exposure SNPs were unlikely to be weak instruments. In both GWAS papers SNPs discovered are related to specific genes, cell types and biological pathways for lung tissue development.

We assume that our SNPs do not affect AD except via their effect on LF/COPD, and that the SNPs have no associations with any confounders that are also associated with AD. Although not possible to directly tests, our sensitivity and heterogeneity tests reduce the risk these assumptions were violated. To account for the possibility of horizontal pleiotropy (IVs affect multiple pathways) we performed MR Egger, weighted median and weighted mode tests.

MR-Egger is similar to IVW except the y intercept is unconstrained. If the y intercept of the MR-Egger is not equal to zero then either there is unbalanced horizontal pleiotropy (the average pleiotropic effect differs from zero) or the pleiotropic effects are independent from the genetic association with the risk factor, or both ⁽³⁾. Although power is lower compared to IVW, the gradient of the MR-Egger gives a causal estimate of the dose–response relationship between the genetic associations with the risk factor and those with the outcome, providing additional evidence for causal affect. To help avoid the effect of unbalanced instruments on an overall estimate of the mean by the IVW method, weighted median and mode MR methods were performed. A weighted median MR gives a consistent estimate of the causal effect when at least 50% of the weight comes from valid IVs, giving a greater robustness with strongly outlying causal estimates ⁽⁴⁾. A weighted mode MR calculates an estimate based on the set of SNPs that form the largest homogenous cluster, which attempts to avoid the impact of invalid instruments ⁽⁵⁾.

There was no evidence of population stratification (when subgroups within a sample are of different genetic ancestry) as assessed by linkage disequilibrium score regression in the original GWAS.

Steiger Filtering

Steiger filtering estimates each SNP's $rsq.exposure$ and $rsq.outcome$ in the outcome population.⁽⁶⁾ Those SNPs that explain more variance in the outcome than exposure are excluded, as they could lead to a reverse causal relationship. SNPs were removed if they explained more variance of the outcome than the exposure. SNPs were removed if they explained more variance of the outcome than the exposure. Necessary information to perform Steiger filtering includes knowing the case and control numbers for each SNP. In our main Alzheimer's meta-analysis outcome population, we only know this for the PGC cohort. Therefore, we assumed that for the SNPs tested for in the ADSP and IGAP cohorts, every SNP had the same case and control number as the overall participant numbers. For ADSP 4,343 cases and 3,165 controls, for IGAP 17,008 cases and 14,471 controls. A prevalence of the outcome as required for Steiger filtering, we stated that the prevalence of the outcome was 0.07. Similarly, we do not know the exact case and control number for each SNP in the COPD exposure. Therefore, we assumed that every SNP had the same case and control number as the total number of case (35,735) and control (222,076) participants in the study. We estimated the prevalence to be 0.1 as per the discovery GWAS. Lung function is a continuous trait, so does not require estimation of prevalence to perform Steiger filtering.

Appendix 3. Details of Sample Populations

Table E1. Description of GWAS samples used

Exposure	Data source (PMID)	Sample size (% cases)	% European	GWAS Adjustment
Lung function	UKBiobank & SpiroMeta	400,102	100	age, age ² , sex, height, smoking status
COPD	25 studies*	257,811 (13.8%)	100	age, age ² , sex, and height
Outcome	Data source (PMID)	Sample size (% cases)	% European	GWAS Adjustment
Alzheimer's Disease	IGAP, ADSP, PGC	79,865 (31%)	100	ADSP&PGC = gender, batch, 4 principal components PGC = age

*Please see supplementary table 1 of reference⁽²⁾ for full table naming each study with description of respective: cases/controls number, smoking status, age, FEV₁% and FEV₁/FVC

Appendix 4. Flow chart of analysis

Study protocols were not pre-registered.

Figure E5. Flow chart of analysis for all lung function trait SNPs⁽¹⁾

Figure E6. Flow chart of analysis for FEV₁ SNPs

Figure E7. Flow Chart of analysis for FVC SNPs

Figure E8. Flow Chart of analysis for effect FEV₁/FVC SNPs

Figure E9. Flow Chart of analysis for COPD liability SNPs⁽²⁾

Appendix 5

Code available on request from corresponding author.

Data used was summary data freely available in supplementary tables or from corresponding authors of GWAS.

References

1. Shrine N, Guyatt AL, Erzurumluoglu AM, Jackson VE, Hobbs BD, Melbourne CA, et al. New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. *Nature Genetics*. 2019;51(3):481-93.
2. Sakornsakolpat P, Prokopenko D, Lamontagne M, Reeve NF, Guyatt AL, Jackson VE, et al. Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. *Nature Genetics*. 2019;51(3):494-505.
3. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *International journal of epidemiology*. 2015;44(2):512-25.
4. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. 2016;40(4):304-14.
5. Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy in Mendelian randomization studies. *Human Molecular Genetics*. 2018;27(R2):R195-R208.
6. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLoS genetics*. 2017;13(11):e1007081.